ZJJF(SH:600668)2025-04-29 08:00Financial Performance - The company's operating revenue for Q1 2025 was CNY 584.14 million, a decrease of 2.91% compared to CNY 601.67 million in the same period last year[3]. - Net profit attributable to shareholders was CNY 582.27 million, a significant increase of 23,878.70% from CNY 2.43 million year-on-year[3]. - Basic and diluted earnings per share reached CNY 1.6922, reflecting a growth of 23,878.70% compared to CNY 0.0071 in the previous year[3]. - The company reported a significant increase in profits from its equity-accounted joint venture, Tian Shili Group, contributing to the overall profit growth[7]. - Net profit for Q1 2025 reached ¥586,517,791.15, significantly up from ¥1,605,059.71 in Q1 2024, marking an increase of 36,517.5%[19]. - Earnings per share for Q1 2025 was ¥1.69, compared to ¥0.01 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,275.94 million, up 9.46% from CNY 7,561.01 million at the end of the previous year[4]. - The company's total assets as of March 31, 2025, amount to RMB 8,275,943,461.79, an increase from RMB 7,561,012,484.20 at the end of 2024[14]. - Current assets total RMB 1,522,970,122.98, up from RMB 1,393,684,642.03 at the end of 2024[13]. - Long-term equity investments increased to RMB 2,390,321,028.26 from RMB 1,872,652,613.67[13]. - The total liabilities amount to RMB 1,984,584,686.57, compared to RMB 1,788,671,683.16 previously[14]. - The total liabilities amounted to ¥2,029,363,924.24, with total equity at ¥6,033,922,856.04 as of the reporting date[15]. Cash Flow - The net cash flow from operating activities was negative CNY 34.63 million, worsening from negative CNY 10.12 million in the same period last year[3]. - The total cash inflow from operating activities was ¥594,975,667.47 in Q1 2025, slightly down from ¥600,617,765.03 in Q1 2024[23]. - The net cash inflow from operating activities was -34,629,437.88, compared to -10,124,178.44 in the previous period, indicating a decline in operational cash flow[24]. - Cash inflow from financing activities was 365,551,352.64, significantly higher than 30,000,000.00 in the prior period, indicating strong financing efforts[25]. - The net cash flow from financing activities was 320,746,720.68, compared to 24,733,579.28, demonstrating improved capital raising[25]. - The total cash and cash equivalents at the end of the period reached 396,681,582.81, up from 153,823,798.93, reflecting a strong liquidity position[25]. Investments and Expenditures - Non-recurring gains and losses amounted to CNY 67.16 million, primarily due to significant non-recurring income from the equity transfer of a joint venture[6]. - The company has engaged in significant equity transfers, including the transfer of 418,306,002 shares (28% of total shares) of Tian Shi Li to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.[11]. - The company reported investment income of ¥569,226,223.68 in Q1 2025, a substantial increase from ¥5,336,114.93 in Q1 2024[19]. - The company reported a development expenditure of RMB 99,765,535.96, slightly up from RMB 95,854,030.78[14]. - Research and development expenses for Q1 2025 were ¥24,833,410.34, up 20.9% from ¥20,575,078.73 in Q1 2024[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,734[9]. - The largest shareholder, Jinhua Tongji State-owned Assets Investment Co., Ltd., holds 55,564,103 shares, accounting for 16.15% of total shares[9]. Operational Efficiency - The weighted average return on equity was 10.19%, an increase of 0.05 percentage points from the previous year[4]. - Total operating costs for Q1 2025 were ¥558,700,690.51, down 8.2% from ¥608,529,424.76 in Q1 2024[18]. - Cash outflow for employee compensation was 84,096,827.72, slightly down from 86,190,561.18, suggesting cost management in personnel expenses[24]. - The cash paid for other operating activities was 78,337,980.58, down from 96,668,333.29, indicating a reduction in operational costs[24]. Future Outlook - The company plans to continue focusing on market expansion and new product development to sustain growth in the upcoming quarters[7]. - The company plans to continue expanding its market presence and developing new technologies, as indicated by ongoing investments in R&D[10].